From: Precision BioLogic Inc.
Date: October 16th, 2025
Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce the strategic acquisition of George King Bio-Medical, Inc., a provider of hemostasis diagnostic products with close ties to the bleeding disorders community.
“Since its founding more than 50 years ago, George King Bio-Medical has remained true to its purpose—helping individuals affected by bleeding disorders,” comments Paul Empey, President and CEO of Precision BioLogic. “Our two organizations share a similar purpose. Together, we can continue to work with existing customers and partners while exploring new opportunities to help others in the bleeding disorders community.”
Kathryn Blasco, CEO and President of George King Bio-Medical and daughter of George King, the company’s founder, agrees. “Joining forces with Precision BioLogic enables us to continue our legacy of compassion and innovation. The future looks promising for us and our customers.”
The two organizations will continue to focus on their customers and regular operations while developing longer term strategic plans under the Precision BioLogic umbrella.